Ching-Chun Lin; Ichiro Takeuchi; Hirotaka Shimizu; Reiko Kyodo; Mitsuru Kubota; Akira Ishiguro; Katsuhiro Arai

doi:10.5217/ir.2024.00154

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Original Article Characteristics and long-term outcomes of children with perianal Crohn’s disease: Ching-Chun Lin^1,2, Ichiro Takeuchi³, Hirotaka Shimizu³, Reiko Kyodo³, Mitsuru Kubota¹, Akira Ishiguro², Katsuhiro Arai^3,; DOI: https://doi.org/10.5217/ir.2024.00154
Published online: March 5, 2025

¹Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan

²Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan

³Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan

Correspondence to Katsuhiro Arai, Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo 157-8535, Japan. E-mail: arai-k@ncchd.go.jp

• Received: September 30, 2024 • Revised: November 28, 2024 • Accepted: December 4, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,630 Views
193 Download

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
The incidence of perianal lesions (PL) in children with Crohn’s disease (CD) is higher in East Asia than in Western countries. Early intervention for PL is essential to prevent sphincter dysfunction and ostomy placement. In this study, we aimed to investigate the clinical features, treatment, and consequences of pediatric CD with PL.
Methods
We retrospectively reviewed a cohort of children diagnosed with CD from 2010 to 2020 at a Japanese children’s hospital. Demographics, treatments, and outcomes were evaluated and compared among subgroups.
Results
Among 112 pediatric patients with CD, 36 (32.1%) had experienced PL during the observational period. The median ages at diagnosis and follow-up periods were 131 and 70 months, respectively. Six (85.7%) patients in the very early-onset (VEO) group (CD diagnosed before 6 years old) and 24 (82.8%) in the older age group had PL upon diagnosis of CD (P= 0.851). Biologics were given to 94.4% of patients: infliximab (67.7%), adalimumab (58.8%), ustekinumab (44.1%), risankizumab (11.8%), and vedolizumab (5.9%). Biologics were introduced within 1 year in 89.5% and 40.0% of patients diagnosed in 2016–2020 and 2010–2016, respectively (P= 0.002). Seton was frequently used in the older age group (87.5 vs. 42.9%, P= 0.190). Ostomy was frequently required in the VEO group (42.9% vs. 0.0%, P= 0.006).
Conclusions
Patients with VEO-CD and PL had a notably high risk of ostomy placement. The earlier introduction of biologics and surgical interventions reduced corticosteroids use and ostomy placement in pediatric CD patients with PL.
Keywords: Children; Crohn disease; Biologics; Inflammatory bowel disease; Surgery

INTRODUCTION

Crohn’s disease (CD) is a lifelong inflammatory condition that affects the gastrointestinal tract and other organs and tissues. The incidence of CD has increased worldwide, including in Asian countries [1]. Perianal lesions (PL), defined by the Paris classification as the presence of a perianal fistula and abscess and/or anal canal ulcers [2], reportedly occur in approximately 10% to 20% of children with CD in Western countries [1,3,4], with the incidence increasing to 34.1%–47.1% in East Asian countries [3]. PL can manifest at the time of diagnosis or later during the disease course causing severe pain, discomfort, and impaired quality of life [5]. Early diagnosis and adequate treatment of PL in CD are essential to prevent complications including sphincter dysfunction or ostomy placement. The medical treatments for PL include antibiotics, immunomodulators, and biologics. Recently, biologics have proven effective in CD patients with PL [6]. Besides infliximab and adalimumab, anti-tumor necrosis factor (TNF)-α drugs that have been used for CD for more than 20 years, new biologics such as ustekinumab (anti-IL12/IL23 p40), vedolizumab (anti-α4β7 integrin), and risankizumab (anti-IL23) have emerged as drugs for adults with CD. These epochal novel medications are relatively safe and effective for adult patients with anti-TNF-α primary or secondary failure [7,8].

Despite the use of various biologics, significant PL can require diversion surgery with ostomy placement in adults [9], with a similar scenario in CD children with PL [10,11]. However, reports on the outcomes of PL in children remain sparse, including in East Asia, where PL is common.

In this study, we investigated the clinical characteristics and outcomes of pediatric CD patients with PL using a cohort of CD patients at a pediatric inflammatory bowel disease (IBD) center in Japan.

METHODS

1. Ethical Statements

This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the National Center for Child Health and Development (approval number: 2023-077). The requirement for written informed consent was waived because of the retrospective design of the study.

2. Study Population

Until March 2023, we retrospectively reviewed the medical records of a cohort of patients younger than 18 years old who were diagnosed with CD based on the revised Porto criteria [12] between January 2010 and December 2020 at our institution (a tertiary children’s hospital in Japan). We included patients with PL, which were defined according to the Paris classification [2] and confirmed either at the time of diagnosis or later during the disease course. Patients initially thought to have CD but were diagnosed to have monogenic IBD were excluded from the study.

3. Study Design and Data Collection

The following parameters were extracted from the medical records: age at CD diagnosis, age at PL diagnosis, Paris classification (age at diagnosis, disease location, and disease behavior), pharmacological treatments for CD and PL (antibiotics, corticosteroids, immunomodulators, biologics, and small-molecule Janus kinase inhibitors [JAKi]), surgical treatments for PL (incision and drainage, seton placement, diversion surgery with ostomy placement, and proctocolectomy), and clinical course (PL recurrence and continuation of biologics). JAKi was counted as a kind of biologic because it was used in only 1 patient in this study.

Patients were classified according to age and year of diagnosis, respectively. We defined the very early-onset (VEO) group as those diagnosed with CD when they were < 6 years of age and the older age group as those diagnosed at ≥ 6 years of age. Those diagnosed in 2010–2015 were defined as the early diagnosis group, whereas those diagnosed in 2016–2020 were defined as the late diagnosis group. Classification by the year of diagnosis was established because ustekinumab, vedolizumab, risankizumab, and upadacitinib were approved for CD after 2017, and the refractory PL management strategy may have changed after that.

Descriptive statistics were expressed as mean with standard deviation, median with interquartile range, and proportions as appropriate. Categorical variables between the groups were compared using the chi-square test. The Fisher exact test was used to evaluate the variables in these groups while comparing the ratio of surgical interventions, as no patient diagnosed after 6 years of age underwent ostomy placement.

RESULTS

1. Patients

Between January 2010 and December 2020, 112 patients were newly diagnosed with CD at our institution. Of the 112 patients, 36 (32.1%) had PL during the disease course. All patients with PL were of Japanese ethnicity. Disease characteristics at the time of CD diagnosis are summarized in Table 1. Among the 36 patients, the median age at diagnosis and the follow-up period were 131 ± 28 and 70 ± 28.3 months, respectively. Seven patients (19.4%) were in the VEO group, and 29 (80.6%) were in the older age group. Our study included more males (63.9%) than females (36.1%). PL were confirmed in 30 patients at the time of CD diagnosis (83.3%) and in 6 patients during follow-up (16.7%). Regarding the disease location, 26 patients (72.2%) had L3, and 27 had L4b (75.0%). For small bowel involvement, represented by L1, L3, or L4b, 4 of the 7 patients in the VEO group had L2, indicating colonic disease without small bowel involvement. The remaining 3 had L3, with 2 also exhibiting L4b involvement. In the older age group, only 2 of the 29 patients lacked small bowel involvement. Three patients in this group had L1 with L4b involvement, while 23 patients had L3, of whom 22 also had L4b. One patient had an isolated L4b lesion in the small intestine. Two of the 36 patients in the VEO group had stenotic lesions (B2) at the time of CD diagnosis; however, none had penetrating bowel lesions (B3). Six of the 7 patients in the VEO group and 10 of the 29 patients in the older age group underwent genetic testing, with 8 patients undergoing whole exome sequencings and 8 undergoing panel sequencing (covering 17 known monogenic IBD genes). However, none of the patients was diagnosed with a known monogenic form of IBD.

2. Medical Treatments

Almost all of the patients with PL received biologics during the course of their disease (34/36, 94.4%). More than half had received more than 2 biologics in the VEO-CD group (57.1%) and the older age group (55.2%) owing to intolerance or primary or secondary failure. Two patients with refractory disease received 4 or 5 different biologics (Figs. 1 and 2).

Infliximab and adalimumab were given to 23 (67.7%) and 20 (58.8%) patients, respectively, covering all patients who had ever been treated with biologics. Ustekinumab was given to 15 patients (44.1%) for secondary failure or intolerance to anti-TNF-α drugs. Risankizumab and vedolizumab were administered to 4 (11.8%) and 2 patients (5.9%), respectively. An oral JAKi drug, upadacitinib, was administered to 1 patient.

At the end of the follow-up period, the PL were well controlled with continued biologic therapies in most cases. Ten patients continued with ustekinumab, 9 with infliximab, 9 with adalimumab, 3 with risankizumab, 1 with vedolizumab, and 1 with upadacitinib. Infliximab was discontinued after 3 doses in 1 patient because of continuous remission.

Thiopurines and 5-aminosalicylic acid were given to 27 (75.0%) and 35 (97.2%) patients, respectively. Corticosteroids were administered to 13 patients, representing 36.1% of our study population. All patients, except for 1 patient who refused to take it, received an elemental formula during their disease course.

Corticosteroids were given to more patients in the early diagnosis group (56.3% vs. 20.0%, P< 0.05). More patients in the late diagnosis group were given biologics within 1 year of diagnosis (89.5% vs. 40.0%, P< 0.05). Ustekinumab was given to more patients in the early diagnosis group (50.0% vs. 10.0%, P< 0.05) (Table 2).

Six of the 7 patients in the VEO group (85.7%) and 24 of the 29 patients in the older age group (82.8%) had PL at the time of CD diagnosis. There were no significant differences between the VEO and older age groups regarding corticosteroid or biologic utilization. The ratio of patients introduced to biologics within 1 year of diagnosis was higher in the older age group; however, no statistical significance was observed (42.9% vs. 69.0%, P= 0.23) (Table 3). Regarding the continued use of biologics, there was no significant difference between the VEO and older age groups.

3. Surgical Intervention

Five patients (13.9%) did not undergo examination under anesthesia, while 21 of the 31 patients who underwent examination under anesthesia required either incision with drainage or seton placement. Over the course of the disease, 28 patients (77.8%) underwent surgical intervention for PL. The procedures ranged from incision with drainage and seton placement to more aggressive interventions such as diversion with ostomy placement or proctocolectomy. Among these 28 patients, 2 of the 4 patients in the VEO group and 18 of the 24 patients in the older age group underwent surgical intervention before the use of biologics. Additionally, 7 of the 12 patients diagnosed before 2016 and 13 of the 16 patients diagnosed in 2016 or after had surgical intervention before the introduction of biologics.

Seton placement was performed in 24 patients (66.7%). Seventeen patients (70.8%) had the seton removed or detached by the end of the follow-up period. Repeated seton placement was required by 2 patients because of recurrent PL. Three of the 7 patients diagnosed with VEO-CD underwent diversion surgery with ostomy placement (sigmoid colon, transverse colon, and terminal ileum). One patient eventually required proctocolectomy and a permanent stoma at the sigmoid colon level. None of the 29 patients in the older age group required bowel surgery.

Twelve patients in the early diagnosis group (75.0%) and 16 in the late diagnosis group (80.0%) had PL at the time of CD diagnosis. Ten patients in the early diagnosis group (62.5%) and 14 in the late diagnosis group (70%) underwent seton placement. The rate of total surgical intervention did not differ significantly between both groups (75.0% vs. 80.0%, P= 0.72) (Table 2). Five of the 7 patients with VEO-CD (71.4%) were in the early diagnosis group, as well as 3 patients who underwent diversion surgery with ostomy placement with/without proctocolectomy.

With the further comparison of the VEO and older age groups, more patients in the older age group required surgical intervention, mainly seton placement (57.1% vs. 82.7%, P=0.14). Upon closer examination of the surgical interventions, we observed that more patients in the older age group underwent less invasive procedures, such as seton placement or incision with drainage (14.3% vs. 82.8%, P< 0.05), whereas patients in the VEO group who required surgical intervention eventually underwent more invasive procedures, such as diversion surgery with ostomy placement with/without proctocolectomy (42.9% vs. 0.0%, P< 0.05).

DISCUSSION

This retrospective analysis of children with CD complicated by PL at a Japanese pediatric IBD center revealed the high prevalence of PL managed mostly with biologics. The treatment outcome was not satisfactory in patients in the VEO group, with 3 out of 7 patients requiring ostomy placement with/without proctocolectomy. The evolving landscape of CD management in patients with PL is characterized by a notable trend towards early introduction and increased utilization of biologic therapies [13]. This paradigm shift offers improved clinical outcomes and an enhanced quality of life. Consequently, this underscores the importance of individualized treatment approaches and ongoing research efforts to optimize the care of this complex patient population. Surgical intervention remains a crucial component of the multidisciplinary management of pediatric CD patients with PL [14,15]. Despite advancements in medical therapy, particularly biologics contributing to reduced surgical resection rates, complex patients require surgical intervention to achieve optimal outcomes.

1. Biologics Play a Key Role in Pediatric CD Patients with PL

Recent medical management guidelines for CD recommend the early introduction of anti-TNF-α drugs for patients with poor outcome predictors, which include perianal disease, stricturing or penetrating disease, extensive disease, deep colonic ulcers, or growth delay [13,15].

Biologics have become a standard treatment for CD since their introduction more than 20 years ago. In the management of pediatric CD patients with PL, recent studies have suggested a clear trend towards the early introduction and increased utilization of biologic therapies, which has shown promising results [6,15]. Various studies have highlighted positive treatment outcomes associated with biologic therapies for PL in pediatric patients with CD [16,17], including higher rates of fistula closure, reduced need for surgical interventions, and enhanced quality of life [17,18]. In our study, 94.4% of patients were given biologics, and in the late diagnosis group (those diagnosed in 2016–2020), up to 90% of patients with PL initiated biologics within 1 year. Biologics have been prescribed for children with VEO-CD who are more vulnerable to the adverse effects of corticosteroids and tend to have more aggressive disease courses that require immediate disease control [19,20].

2. Types of Biologics

Among the biologics used in treating pediatric CD patients with PL, infliximab and adalimumab have demonstrated good efficacy [17,18,21]. Ruemmele et al. [17] highlighted the significance of adalimumab in achieving fistula closure and improving disease outcomes in the pediatric population. The efficacy of infliximab in inducing and maintaining remission in pediatric CD patients with PL has been evaluated [13,22,23].

The role of vedolizumab in managing IBD, including in adult CD patients with PL, has been investigated [7]. Atia et al. [24] presented data on its effectiveness and dosing considerations for pediatric patients with CD but with little evidence on PL. Two of our patients received vedolizumab, and 1 had it discontinued due to worsening scalp folliculitis.

Ustekinumab has been used as a superior therapeutic option in adults with CD, with or without PL [7,25,26]. It has also been introduced to pediatric patients [27].

Risankizumab effectively induced remission in moderate-to-severe PL in CD [28]; however, more research is needed to establish its specific role in pediatric patients with PL. Four of our 36 CD patients with PL received risankizumab to control the CD, and not primarily for the PL; nevertheless, 3 of them achieved better control of the CD without worsening the PL.

Upadacitinib, used for atopic dermatitis in children ≥ 12 years old, was approved for adult ulcerative colitis and CD. It is occasionally introduced to pediatric patients with refractory disease; however, it still requires further investigation [29,30]. Symptomatic control of CD with upadacitinib was achieved in one of our patients, who experienced intolerance to most previously administered biologics, and PL was controlled. There are limited published data on the effects of JAKi on PL [31]. Overall, the choice of biologics for pediatric CD patients with PL should be based on individual patient factors, disease severity, and response to previous treatments, while also considering the available evidence regarding the efficacy and safety profile of each biologic agent. The availability of newer biologics with distinct mechanisms of action offers additional therapeutic options and the potential for treatment approaches tailored to individual patient characteristics and preferences.

Furthermore, darvadstrocel, a suspension of allogenic adipose-derived mesenchymal stem cells developed as a one-time local injection for the treatment of complex perianal fistulas in adults with CD, has been reported to be safe and effective [32-34]. However, there are few reports available to date on its use in pediatric patients. Close monitoring and multidisciplinary management are essential to optimize treatment outcomes in this challenging patient population.

3. VEO-CD

Patients with VEO-CD exhibit distinct characteristics compared to those with older-onset pediatric CD [35,36]. The disease behavior in patients with VEO-CD is usually more inflammatory and non-stricturing than that in the older-onset group and often presents with a more isolated colonic disease [37]. In contrast, the disease course in VEO-CD could be more aggressive with greater perianal involvement, eventually causing more severe growth retardation [37]. Patients with VEO-CD may require aggressive medical therapy, including early initiation of biologics such as anti-TNF-α or IL-12/23 [35]. Despite aggressive medical management, patients with VEO-CD may require invasive surgical intervention, usually at a higher rate than patients with older-onset pediatric CD [35,38]. Due to refractory responses to medical therapy or disease complications, studies have reported a higher likelihood of patients with VEO-CD requiring early surgical intervention, including bowel resection, stoma formation, or perianal surgeries [38].

As the majority of the patients with VEO-CD received biologics, with over half being treated with corticosteroids, the requirement for surgical intervention may be invasive, such as ostomy or colectomy. The fact that our patients with VEO-CD requiring ostomy placement with/without proctocolectomy came from the early diagnosis group implies that earlier initiation of biologics with additional choices if it fails might lessen the need for invasive surgical management, such as ostomy placement.

Bor et al. [39] demonstrated the efficacy of combined anti-TNF-α and surgical therapy in adults, such as seton placement, in treating perianal and enterocutaneous fistulizing CD. Half of the patients achieved complete fistula closure within 1 year, and its success has been recognized in the pediatric population [22,40]. Our results are consistent with these findings. Ashton et al. [23] noted that an increased utilization of anti-TNF therapy was associated with a decline in surgical resection in pediatric patients with IBD. This trend suggests the potential impact of medical therapy in reducing the need for surgical intervention.

4. Limitation and Conclusion

The limitations of our study include its retrospective nature, limited patient enrollment from a single center, the lack of therapeutic drug monitoring, and changes in evolving treatment strategies, especially with the introduction of newly approved biologics. However, these management changes have improved the outcomes of pediatric CD patients with PL. Although we defined PL according to the Paris classification, further details of PL were not described because of the study’s retrospective nature and the non-standardized description of PL. Additionally, this study did not compare pediatric CD patients with PL to that without PL, as it was beyond the scope of the study. Further research involving data from a larger cohort of pediatric-onset CD with and without PL would help clarify the factors that influence the outcome of PL.

The early use of biologics and appropriate surgical intervention could improve the outcome of children with CD and PL. The use of newly approved biologics offers the option of controlling PL in cases refractory to anti-TNF-α drugs. VEO-CD complicated by PL should be considered a high-risk group for invasive surgical procedures.

NOTES

Funding Source

This work was supported in part by Health and Labor Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labor and Welfare of Japan.

Conflict of Interest

Takeuchi I received honoraria from Takeda Pharmaceutical Corporation and AbbVie GK. Shimizu H received honoraria from Takeda Pharmaceutical Corporation and AbbVie GK and a research grant from AbbVie GK. Arai K received honoraria from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Corporation, and AbbVie GK and research grants from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Corporation, and AbbVie GK. The remaining authors have no conflicts of interest to declare.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author, Arai K. The data are not publicly available due to the presence of information that could compromise the privacy of patients.

Author Contributions

Conceptualization; Investigation; Methodology; Project administration: Lin CC, Kyodo R, Arai K. Data curation: Lin CC, Takeuchi I, Kyodo R, Shimizu H, Arai K. Funding acquisition: Arai K. Validation; Visualization: Lin CC, Takeuchi I, Shimizu H, Arai K. Supervision: Kubota M, Ishiguro A, Arai K. Writing – original draft: Lin CC. Writing - review & editing: Lin CC, Kubota M, Ishiguro A, Arai K. Approval of final manuscript: all authors.

Fig. 1.

Biologics used by different age groups. The entire very early onset (VEO) group and 93.1% of the older age group have received biologics, with more than half of them had received more than 2 biologics.

Fig. 2.

The number of biologics used in each patient (n=36). Single and 2 biologics were used in more than 70% of the patients. One patient had received 5 biologics.

Table 1.

Demographics of Children with CD Complicated with PL

Characteristic	Value (n = 36)
Age at diagnosis (mo)
Median (IQR)	131 (112–168)
Range	0–199
Sex, No. (%)
Male	23 (63.9)
Female	13 (36.1)
Follow-up period (mo), median (IQR)	70 (42.5-99.0)
Classification by age at diagnosis, No. (%)
VEO group (< 6 yr)	7 (19.4)
Older age group (≥ 6 yr)	29 (80.6)
Classification by year of diagnosis, No. (%)
Earlier diagnosis group (2010–2015)	16 (44.4)
Later diagnosis group (2016–2020)	20 (55.6)
Timing of PL diagnosis, No. (%)
At CD diagnosis	30 (83.3)
During the follow-up	6 (16.7)
Paris classification^a
Age at diagnosis, No. (%)
A1a	13 (36.1)
A1b	22 (61.1)
A2	1 (2.8)
Location, No. (%)
L1+L4a+L4b	3 (8.3)
L2	5 (13.9)
L2+L4a	1 (2.8)
L3	2 (5.6)
L3+L4a	1 (2.8)
L3+L4b	5 (13.9)
L3+L4a+L4b	18 (50.0)
L4a+L4b	1 (2.8)
Behavior, No. (%)
B1	34 (94.4)
B2	2 (5.6)
B3	0

^a Age at diagnosis: A1a (≤10 years old), A1b (10 to <17 years old), A2 (17 to 40 years old); Disease location at diagnosis: L1 (distal 1/3 of ileum±cecal involvement), L2 (colonic), L3 (ileocolonic), L4a (upper disease proximal to ligament of Treitz), L4b (upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum); Disease behavior at diagnosis: B1 (nonstricturing, nonpenetrating), B2 (stricturing), B3 (penetrating).

CD, Crohn’s disease; PL, perianal lesion; IQR, interquartile range; VEO, very early onset.

Table 2.

Shift in Treatment by the Year of Diagnosis

Variable	Early diagnosis group (2010–2015) (n = 16)	Late diagnosis group (2016–2020) (n = 20)	P-value
Patient characteristics
VEO	5 (31.3)	2 (10.0)	0.20
PL at diagnosis	12 (75.0)	18 (90.0)	0.23^a
Treatments
Corticosteroids	9 (56.3)	4 (20.0)	< 0.05^a
No biologics nor seton	1 (6.3)	0	1.00
Any biologic use during FU	15 (93.8)	19 (95.0)	1.00
Early introduction of biologics	6 (40.0)	17 (89.5)	< 0.05
Biologics at the last FU
Infliximab	2 (12.5)	7 (35.0)	0.25
Adalimumab	3 (18.6)	6 (30.0)	0.70
Vedolizumab	1 (6.3)	0	0.44
Ustekinumab	8 (50.0)	2 (10.0)	< 0.05
Risankizumab	1 (6.3)	2 (10.0)	1.00
Upadacitinib	0	1 (5.0)	1.00
Surgical interventions
Seton placement	4 (25.0)	9 (45.0)	0.30
Incision and drainage	2 (12.5)	2 (10.0)	1.00
Seton+incision & drainage	3 (18.8)	5 (25.0)	1.00
Seton+ostomy with/without proctocolectomy	3 (18.8)	0	0.08
No surgical intervention	4 (25.0)	4 (20.0)	1.00
Outcomes
Fistula healing and PL remission	8 (50.0)	18 (90.0)	< 0.05
Seton detachment	6 (60.0)	11 (78.6)	0.34

Values are presented as number (%).

^a Chi-square test.

VEO, very early onset; PL, perianal lesions; FU, follow-up.

Table 3.

Treatment Outcome of Perianal Disease by Age Group

Variable	VEO group (n = 7)	Older age group (n = 29)	P-value
PL at diagnosis	6 (85.7)	24 (82.8)	0.85^a
MRI examined	3 (42.9)	23 (79.3)
Treatments
Corticosteroids	4 (57.1)	9 (31.0)	0.23
No biologics nor seton	1 (14.3)	2 (6.9)	0.53^a
Any biologic use during FU	7 (100)	27 (93.1)	1.00
Early introduction of biologics	3 (42.9)	20 (69.0)	0.23
Biologics at the last FU
Infliximab	0	9 (31.0)	0.16
Adalimumab	2 (28.6)	7 (24.1)	0.06^a
Vedolizumab	1 (12.3)	0	0.19
Ustekinumab	3 (42.9)	7 (24.1)	0.37
Risankizumab	0	3 (10.3)	1.00
Upadacitinib	0	1 (3.5)	1.00
Surgical interventions	4 (57.1)	24 (82.8)	0.17
Seton placement	0	13 (44.8)	< 0.05
Incision and drainage	1 (14.3)	3 (10.3)	1.00
Seton+incision & drainage	0	8 (27.6)	0.31
Seton+ostomy with/without proctocolectomy	3 (42.9)	0	< 0.05
No surgical intervention	4 (57.1)	24 (82.7)	0.17
Outcomes
Fistula healing and PL remission	4 (57.1)	21 (72.4)	0.65
Seton detachment	3 (100.0)	13 (61.9)	0.66

Values are presented as number (%).

^a Chi-square test.

VEO, very early onset; PL, perianal lesions; MRI, magnetic resonance image; FU, follow-up.

REFERENCES

1. Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 2022;162:1147–1159.Article PubMed
2. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314–1321.PubMed
3. Lee WS, Arai K, Alex G, et al. Medical management of pediatric inflammatory bowel disease (PIBD) in the Asia Pacific Region: a position paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group. J Gastroenterol Hepatol 2023;38:523–538.
4. Brückner A, Werkstetter KJ, de Laffolie J, et al. Incidence and risk factors for perianal disease in pediatric crohn disease patients followed in CEDATA-GPGE Registry. J Pediatr Gastroenterol Nutr 2018;66:73–78.Article PubMed
5. Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. J Pediatr Psychol 2010;35:857–869.Article PubMed PMC
6. De La Puente S, Espinosa Góngora R, Souto Romero H, et al. Pediatric perianal Crohn’s disease behavior in the era of biologic therapy. Cir Pediatr 2023;36:22–27.Article PubMed
7. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology 2021;160:2512–2556.Article PubMed PMC
8. Godoy Brewer GM, Salem G, Afzal MA, et al. Ustekinumab is effective for perianal fistulising Crohn’s disease: a real-world experience and systematic review with meta-analysis. BMJ Open Gastroenterol 2021;8:e000702.Article PubMed PMC
9. McCurdy JD, Reid J, Yanofsky R, et al. Fecal diversion for perianal Crohn disease in the era of biologic therapies: a multicenter study. Inflamm Bowel Dis 2022;28:226–233.Article PubMed PDF
10. Kurowski JA, Milinovich A, Ji X, et al. Differences in biologic utilization and surgery rates in pediatric and adult Crohn’s disease: results from a large electronic medical record-derived cohort. Inflamm Bowel Dis 2021;27:1035–1044.Article PubMed PDF
11. Atia O, Focht G, Lujan R, et al. Perianal Crohn disease is more common in children and is associated with complicated disease course despite higher utilization of biologics: a population-based study from the epidemiology group of the Israeli IBD Research Nucleus (epiIIRN). J Pediatr Gastroenterol Nutr 2022;74:788–793.Article PubMed
12. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795–806.Article PubMed
13. van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2021;15:171–194.Article PDF
14. Amil-Dias J, Kolacek S, Turner D, et al. Surgical management of Crohn disease in children: guidelines from the paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2017;64:818–835.Article PubMed
15. Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn’s disease. Inflamm Bowel Dis 2009;15:383–387.Article PubMed
16. Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009;49:183–190.Article PubMed
17. Ruemmele FM, Rosh J, Faubion WA, et al. Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn’s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis 2018;12:1249–1254.Article PubMed PMC
18. Iwańczak BM, Ryżko J, Jankowski P, et al. Induction and maintenance infliximab therapy for the treatment of Crohn’s disease with perianal fistulas in children: retrospective, multicenter study. Adv Clin Exp Med 2016;25:523–530.Article PubMed
19. Takeuchi I, Kaburaki Y, Arai K, et al. Infliximab for very early-onset inflammatory bowel disease: a tertiary center experience in Japan. J Gastroenterol Hepatol 2020;35:593–600.Article PubMed PDF
20. Eindor-Abarbanel A, Meleady L, Lawrence S, et al. Progression to anti-TNF treatment in very early onset inflammatory bowel disease patients. J Pediatr Gastroenterol Nutr 2022;75:473–479.Article PubMed
21. Carnovale C, Maffioli A, Zaffaroni G, et al. Efficacy of tumour necrosis factor-alpha therapy in paediatric Crohn’s disease patients with perianal lesions: a systematic review. Expert Opin Biol Ther 2020;20:239–251.Article PubMed
22. Hukkinen M, Pakarinen MP, Piekkala M, Koivusalo A, Rintala R, Kolho KL. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn’s disease. J Crohns Colitis 2014;8:756–762.Article PubMed
23. Ashton JJ, Borca F, Mossotto E, et al. Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther 2019;49:398–407.Article PubMed PDF
24. Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol 2023;8:31–42.Article PubMed
25. Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn’s disease: the BioLAP multicenter study from the GETAID. Am J Gastroenterol 2020;115:1812–1820.Article PubMed
26. Yao J, Zhang H, Su T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn’s disease: a retrospective real-world analysis. J Clin Med 2023;12:939.Article PubMed PMC
27. Kim FS, Patel PV, Stekol E, et al. Experience using ustekinumab in pediatric patients with medically refractory Crohn disease. J Pediatr Gastroenterol Nutr 2021;73:610–614.Article PubMed PMC
28. Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699–1709.Article PubMed
29. Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med 2023;388:1966–1980.Article PubMed
30. Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn’s disease. Inflamm Bowel Dis 2023;29:1175–1176.Article PubMed PDF
31. Friedberg S, Choi D, Hunold T, et al. Upadacitinib is effective and safe in both ulcerative colitis and Crohn’s disease: prospective real-world experience. Clin Gastroenterol Hepatol 2023;21:1913–1923.Article PubMed PMC
32. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016;388:1281–1290.PubMed
33. Furukawa S, Mizushima T, Nakaya R, et al. Darvadstrocel for complex perianal fistulas in Japanese adults with Crohn’s disease: a phase 3 study. J Crohns Colitis 2023;17:369–378.Article PubMed PMC PDF
34. Taxonera C, García-Brenes MA, Olivares D, López-García ON, Zapater R, Alba C. Darvadstrocel for complex perianal fistulas in Crohn’s disease: a systematic review and meta-analysis. United European Gastroenterol J 2024;Oct 3 [Epub]. https://doi.org/10.1002/ueg2.12673.Article
35. Kelsen JR, Conrad MA, Dawany N, et al. The unique disease course of children with very early onset-inflammatory bowel disease. Inflamm Bowel Dis 2020;26:909–918.Article PubMed PMC PDF
36. Kudo T, Arai K, Uchida K, et al. Very early-onset inflammatory bowel disease in Japan: a nationwide survey. J Gastroenterol Hepatol 2021;36:151–155.Article PubMed PDF
37. Oliva-Hemker M, Hutfless S, Al Kazzi ES, et al. Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large North American cohort. J Pediatr 2015;167:527–532.Article PubMed
38. Yeh PJ, Chen CC, Chao HC, et al. High initial bowel resection rate and very-early-onset inflammatory bowel disease: a challenge in a low-prevalence area. J Formos Med Assoc 2021;120(1 Pt 3): 720–727.Article PubMed
39. Bor R, Farkas K, Bálint A, et al. Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn’s disease: clinical observations from a tertiary Eastern European center. Scand J Gastroenterol 2015;50:182–187.Article PubMed
40. Seemann NM, Elkadri A, Walters TD, Langer JC. The role of surgery for children with perianal Crohn’s disease. J Pediatr Surg 2015;50:140–143.Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Characteristics and long-term outcomes of children with perianal Crohn’s disease

DOI: https://doi.org/10.5217/ir.2024.00154

XML Download

Figure

Characteristics and long-term outcomes of children with perianal Crohn’s disease

Fig. 1. Biologics used by different age groups. The entire very early onset (VEO) group and 93.1% of the older age group have received biologics, with more than half of them had received more than 2 biologics.

Fig. 2. The number of biologics used in each patient (n=36). Single and 2 biologics were used in more than 70% of the patients. One patient had received 5 biologics.

Fig. 1.

Fig. 2.

Characteristics and long-term outcomes of children with perianal Crohn’s disease

Characteristic	Value (n = 36)
Age at diagnosis (mo)
Median (IQR)	131 (112–168)
Range	0–199
Sex, No. (%)
Male	23 (63.9)
Female	13 (36.1)
Follow-up period (mo), median (IQR)	70 (42.5-99.0)
Classification by age at diagnosis, No. (%)
VEO group (< 6 yr)	7 (19.4)
Older age group (≥ 6 yr)	29 (80.6)
Classification by year of diagnosis, No. (%)
Earlier diagnosis group (2010–2015)	16 (44.4)
Later diagnosis group (2016–2020)	20 (55.6)
Timing of PL diagnosis, No. (%)
At CD diagnosis	30 (83.3)
During the follow-up	6 (16.7)
Paris classification^a
Age at diagnosis, No. (%)
A1a	13 (36.1)
A1b	22 (61.1)
A2	1 (2.8)
Location, No. (%)
L1+L4a+L4b	3 (8.3)
L2	5 (13.9)
L2+L4a	1 (2.8)
L3	2 (5.6)
L3+L4a	1 (2.8)
L3+L4b	5 (13.9)
L3+L4a+L4b	18 (50.0)
L4a+L4b	1 (2.8)
Behavior, No. (%)
B1	34 (94.4)
B2	2 (5.6)
B3	0

Variable	Early diagnosis group (2010–2015) (n = 16)	Late diagnosis group (2016–2020) (n = 20)	P-value
Patient characteristics
VEO	5 (31.3)	2 (10.0)	0.20
PL at diagnosis	12 (75.0)	18 (90.0)	0.23^a
Treatments
Corticosteroids	9 (56.3)	4 (20.0)	< 0.05^a
No biologics nor seton	1 (6.3)	0	1.00
Any biologic use during FU	15 (93.8)	19 (95.0)	1.00
Early introduction of biologics	6 (40.0)	17 (89.5)	< 0.05
Biologics at the last FU
Infliximab	2 (12.5)	7 (35.0)	0.25
Adalimumab	3 (18.6)	6 (30.0)	0.70
Vedolizumab	1 (6.3)	0	0.44
Ustekinumab	8 (50.0)	2 (10.0)	< 0.05
Risankizumab	1 (6.3)	2 (10.0)	1.00
Upadacitinib	0	1 (5.0)	1.00
Surgical interventions
Seton placement	4 (25.0)	9 (45.0)	0.30
Incision and drainage	2 (12.5)	2 (10.0)	1.00
Seton+incision & drainage	3 (18.8)	5 (25.0)	1.00
Seton+ostomy with/without proctocolectomy	3 (18.8)	0	0.08
No surgical intervention	4 (25.0)	4 (20.0)	1.00
Outcomes
Fistula healing and PL remission	8 (50.0)	18 (90.0)	< 0.05
Seton detachment	6 (60.0)	11 (78.6)	0.34

Variable	VEO group (n = 7)	Older age group (n = 29)	P-value
PL at diagnosis	6 (85.7)	24 (82.8)	0.85^a
MRI examined	3 (42.9)	23 (79.3)
Treatments
Corticosteroids	4 (57.1)	9 (31.0)	0.23
No biologics nor seton	1 (14.3)	2 (6.9)	0.53^a
Any biologic use during FU	7 (100)	27 (93.1)	1.00
Early introduction of biologics	3 (42.9)	20 (69.0)	0.23
Biologics at the last FU
Infliximab	0	9 (31.0)	0.16
Adalimumab	2 (28.6)	7 (24.1)	0.06^a
Vedolizumab	1 (12.3)	0	0.19
Ustekinumab	3 (42.9)	7 (24.1)	0.37
Risankizumab	0	3 (10.3)	1.00
Upadacitinib	0	1 (3.5)	1.00
Surgical interventions	4 (57.1)	24 (82.8)	0.17
Seton placement	0	13 (44.8)	< 0.05
Incision and drainage	1 (14.3)	3 (10.3)	1.00
Seton+incision & drainage	0	8 (27.6)	0.31
Seton+ostomy with/without proctocolectomy	3 (42.9)	0	< 0.05
No surgical intervention	4 (57.1)	24 (82.7)	0.17
Outcomes
Fistula healing and PL remission	4 (57.1)	21 (72.4)	0.65
Seton detachment	3 (100.0)	13 (61.9)	0.66

Table 1. Demographics of Children with CD Complicated with PL

Age at diagnosis: A1a (≤10 years old), A1b (10 to <17 years old), A2 (17 to 40 years old); Disease location at diagnosis: L1 (distal 1/3 of ileum±cecal involvement), L2 (colonic), L3 (ileocolonic), L4a (upper disease proximal to ligament of Treitz), L4b (upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum); Disease behavior at diagnosis: B1 (nonstricturing, nonpenetrating), B2 (stricturing), B3 (penetrating).

CD, Crohn’s disease; PL, perianal lesion; IQR, interquartile range; VEO, very early onset.

Table 2. Shift in Treatment by the Year of Diagnosis

Values are presented as number (%).

Chi-square test.

VEO, very early onset; PL, perianal lesions; FU, follow-up.

Table 3. Treatment Outcome of Perianal Disease by Age Group

Values are presented as number (%).

Chi-square test.

VEO, very early onset; PL, perianal lesions; MRI, magnetic resonance image; FU, follow-up.